Amin Sharifan, PharmD

Dobrescu, A.I.; Pinte, L.; Sharifan, A.; Gadinger, A.; Moser, I.; Cooper, C.; Gartlehner, G. (2026). Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-05044.

Kang, J.; et. al.; Sharifan, A. (2026). Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study. Nature Medicine, 32: 527-544

Moser, T.K.; Dobrescu, A.I.; Sommer, I.; Goeschl, S.; Sharifan, A.; Ledinger, D.; Klerings, I.; Gartlehner, G. (2026). Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-05536.

Oh, J.; et. al.; Sharifan, A. (2026). Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study. Nature Medicine, 32: 197-223

Sharifan, A. (2026). Misrepresentation of nonsignificant results: reporting pitfalls in urology randomised trials. BJU International, https://doi.org/10.1111/bju.70139: https://doi.org/10.1111/bju.70139

Sharifan, A.; Dobrescu, A.I.; Klerings, I.; Gartlehner, G. (2026). Update Alert 4: Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-26-00504.

Sommer, I. Dobrescu, A. Gadinger, A. Sharifan, A. Pinte, L. Fangmeyer, M. Klerings, I. Gartlehner, G. (2026). Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3). Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-03691.

Ryan-Vig, S.; Sharifan, A. (2026). For people undergoing first-line treatment for advanced pancreatic cancer, how do gemcitabine-containing dual chemotherapy regimens compare with gemcitabine alone? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4689: https://doi.org/10.1002/cca.4689

Sharifan, A. (2026). In children with nocturnal enuresis, how does desmopressin therapy alone compare with desmopressin combination therapy (adding alarm therapy or other medications, such as anticholinergics or tricyclics)? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4711: https://doi.org/10.1002/cca.4711

Sharifan, A. (2026). For people undergoing first-line treatment for advanced pancreatic cancer, how do different chemotherapy combinations compare with gemcitabine plus nab-paclitaxel? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4691: https://doi.org/10.1002/cca.4691

Sharifan, A. (2026). In children with nocturnal enuresis, how does desmopressin compare with no treatment or placebo, alarm therapy, or other medications such as tricyclics, anticholinergics, or non-steroidal anti-inflammatory drugs? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4710: https://doi.org/10.1002/cca.4710

Sharifan, A. (2026). What are the benefits and harms of weekly SARS-CoV-2 testing compared with no routine testing for residents and healthcare workers in long-term care facilities? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4722: https://doi.org/10.1002/cca.4722

Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of once-weekly tirzepatide injections compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4733: https://doi.org/10.1002/cca.4733

Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of daily liraglutide injections compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4735: https://doi.org/10.1002/cca.4735

Sharifan, A. (2026). For the prevention of respiratory syncytial virus (RSV) disease in infants and children, what are the benefits and harms of maternal vaccination during pregnancy, and infant or child vaccination? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4715: https://doi.org/10.1002/cca.4715

Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of semaglutide injections compared with liraglutide injections? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4732: https://doi.org/10.1002/cca.4732

Sharifan, A. (2026). Among older adults (aged = 60 years), what are the benefits and harms of respiratory syncytial virus (RSV) vaccines (either RSV prefusion vaccines or RSV postfusion F protein-based vaccines) compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4714: https://doi.org/10.1002/cca.4714

Sharifan, A. (2026). Among healthy women of childbearing age who are not pregnant, what are the benefits and harms of respiratory syncytial virus (RSV) recombinant F nanoparticle vaccine compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4716: https://doi.org/10.1002/cca.4716

Sharifan, A. (2026). What are the benefits and harms of riboflavin supplements (vitamin B2) for lowering blood pressure in adults? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4727: https://doi.org/10.1002/cca.4727

Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of once-weekly tirzepatide injections compared with once-weekly semaglutide injections? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4734: https://doi.org/10.1002/cca.4734